Has Charles Hollen received payments from drug or device companies?

Yes. Drug and device makers reported $10,371 in general payments to Charles Hollen across 512 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charles Hollen did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charles Hollen come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charles Hollen

Hematology & Oncology · Oklahoma City, OKNPI 1205855723

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,028 of the $10,371 with a category attached, or 77.4%. It is spread thinly across 50 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,814 and has fallen 98.3% since, to $49 in 2024.

$10,371in general payments, 2019–2025

Across 512 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2K
Johnson & Johnson$940
Pfizer$766
Seagen Inc.$726
AstraZeneca$483
Lilly USA, LLC$393
plus $5K from 44 others

What the payments were for

Food & beverage$8,02877%
Education$1,32813%
Other$1,01510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	53	$1,681
Johnson & Johnson	32	$940
Pfizer	47	$766
Seagen Inc.	29	$726
AstraZeneca(2 entities)	27	$483
Lilly USA, LLC	24	$393
Amgen	21	$348
E.r. Squibb & Sons, L.L.C.	22	$320
Merck	20	$309
Genentech USA, Inc.	16	$305
Bristol Myers Squibb	18	$262
Daiichi Sankyo Inc.	13	$254
Astellas Pharma US Inc	15	$250
Sanofi	12	$235
Puma Biotechnology, Inc.	10	$196
Pharmacyclics LLC, An Abbvie Company	8	$177
Boehringer Ingelheim	13	$173
Incyte Corporation	9	$154
AbbVie	7	$136
Karyopharm Therapeutics Inc.	6	$134
Eisai Inc.	8	$132
Beigene USA, Inc.	6	$122
Takeda Pharmaceuticals U.S.A., Inc.	6	$121
EMD Serono, Inc.	7	$120
Gilead(2 entities)	7	$115
Array Biopharma Inc	5	$114
Regeneron Healthcare Solutions, Inc.	4	$112
Tersera Therapeutics LLC	5	$107
AVEO Pharmaceuticals, Inc.	5	$103
Mirati Therapeutics, Inc.	5	$91
Ipsen Biopharmaceuticals, Inc	5	$89
Myovant Sciences Inc.	4	$89
CTI Biopharma Corp.	4	$81
Verastem, Inc.	5	$75
Teva Pharmaceuticals USA, Inc.	4	$69
Sobi, Inc	3	$67
Bayer	3	$61
Myriad Genetic Laboratories, Inc.	3	$60
Taiho Oncology, Inc.	3	$55
Genentech, Inc.	1	$50
Foundation Medicine, Inc.	3	$46
G1 Therapeutics, Inc.	2	$42
Stemline Therapeutics Inc.	2	$40
Blueprint Medicines Corporation	2	$40
Spectrum Pharmaceuticals Inc.	2	$34
Fortovia Therapeutics, Inc.	2	$28
ADC Therapeutics America, Inc.	1	$20
Tesaro, Inc.	1	$19
Exelixis Inc.	1	$18
Clovis Oncology, Inc.	1	$10

How this compares

$10,371 in reported general payments places this provider in the 80th percentile of 118 hematology & oncology providers in Oklahoma.

See all hematology & oncology providers in Oklahoma →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Letrozole	18	$514
Citalopram HbrCitalopram Hydrobromide	11	$88

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Oklahoma City

Romeo MandanasOklahoma City$160K
Mohammad RazaqOklahoma City$56K
Sami IbrahimiOklahoma City$41K
Jennifer Holter-ChakrabartyOklahoma City$39K
Hassan HatoumOklahoma City$23K
Abdul Rafeh NaqashOklahoma City$23K
Taha Al-JuhaishiOklahoma City$23K
Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
Robert ReynoldsOklahoma City$15K
Sadia ChohanOklahoma City$13K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →